Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China
Compared with the combined regimen, the use of IDegLira for Chinese patients with type 2 diabetes can improve long-term health output, save medical costs, and is a dominant scheme.
Authors
- Junling Weng
- Xing Chang (ORCID: https://orcid.org/0000-0002-3788-9881)
- Yingyao Chen (ORCID: https://orcid.org/0000-0002-3470-0748)
- Lei Zhang (ORCID: https://orcid.org/0000-0002-0428-4800)
- Wei Yan (ORCID: https://orcid.org/0009-0004-3812-4751)
- Dunming Xiao
Institutions
- Fudan University (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1371/journal.pone.0310497
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Novo Nordisk